Protease activity of the API2-MALT1 fusion oncoprotein in MALT lymphoma development and treatment

Future Oncology

Volumn 7, Issue 5, 2011, Pages 613-617

  Rosebeck, Shaun ^a   Lucas, Peter C ^b   McAllister Lucas, Linda M ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

A20; API2MALT1; Bcl10; chromosomal translocation; lymphoma; MALT1 protease; NIK

Indexed keywords

HYBRID PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 2; INHIBITOR OF APOPTOSIS PROTEIN 2 MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA 1 FUSION PROTEIN; ONCOPROTEIN; PROTEINASE; UNCLASSIFIED DRUG;

ANTIBIOTIC THERAPY; ARTICLE; B LYMPHOCYTE; CANCER STAGING; CANCER SURVIVAL; ENZYME ACTIVITY; HELICOBACTER PYLORI; HUMAN; LYMPHOCYTE FUNCTION; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; TUMOR GROWTH;

HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; NF-KAPPA B; ONCOGENE PROTEINS, FUSION; PEPTIDE HYDROLASES; SIGNAL TRANSDUCTION; TRANSLOCATION, GENETIC;

EID: 79956118582     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.35     Document Type: Article

References (25)

1. Zucca E, Bertoni F, Stathis A, Cavallis F: Marginal Zone Lymphomas. Hemat. Oncol. Clin. N. Am. 22, 883-901 (2008).
2. Sagaert X, De Wolf-Peeters C, Noels H, Baens M: The pathogenesis of MALT lymphomas: where do we stand? Leukemia 21, 389-396 (2007).
3. Du M-Q: MALT lymphoma: many roads lead to nuclear factor-kB activation. Histopathology 58, 26-38 (2011).
4. Isaacson PG, Du M-Q: MALT lymphoma: from morphology to molecules. Nat. Rev. Cancer 4, 644-653 (2004). (Pubitemid 39025059)
5. Lucas PC, Yonezumi M, Inohara N, et al.: Bcl10 and MALT1, independent targets of chromosomal translocation in MALT lymphoma, cooperate in a novel NF-κB signaling pathway. J. Biol. Chem. 276, 19012-19019 (2001).
6. Sun L, Deng L, Ea C-K, Xia Z-P, Chen ZJ: The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol. Cell. 14, 289-301 (2004). (Pubitemid 38591401)
7. Thome M: Multifunctional roles for MALT1 in T-cell activation. Nat. Rev. Immunol. 8, 495-500 (2008). (Pubitemid 351913678)
8. Zhou H, Du M-Q, Dixit VM: Constitutive NF-κB activation by the t(11;18)(q21;q21) product in MALT lymphoma is linked to deregulated ubiquitin ligase activity. Cancer Cell 7, 425-431 (2005). (Pubitemid 40719126)
9. Lucas PC, Kuffa P, Gu S, et al.: A dual role for the API2 moiety in API2-MALT1-dependent NF-κB activation: heterotypic oligomerization and TRAF2 recruitment. Oncogene 26, 5643-5654 (2007). (Pubitemid 47267834)
10. Uren AG, ORourke K, Aravind L, et al.: Identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma. Mol. Cell. 6, 961-967 (2000).
11. Snipas SJ, Wildfang E, Nazif T, et al.: Characteristics of the caspase-like catalytic domain of human paracaspase. Biol. Chem. 385(11), 1093-1098 (2004). (Pubitemid 39600319)
12. Rebeaud F, Hailfinger S, Posevitz-Fejfar A, et al.: The proteolytic activity of the paracaspase MALT1 is key to T cell activation. Nat. Immunol. 9, 272-281 (2008). (Pubitemid 351267324)
13. Coornaert B, Baens M, Heyninck T, et al.: T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-κB inhibitor A20. Nat. Immunol. 9, 263-271 (2008). (Pubitemid 351267323)
14. Ferch U, Kloo B, Gewies A, et al.: Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells. J. Exp. Med. 206(11), 2313-2320 (2009).
15. Hailfinger S, Lenz G, Ngo V, et al.: Essential role of MALT1 proteases activity in activated B cell-like diffuse large B-cell lymphoma. PNAS 106(47), 19946-19951 (2009).
16. Rosebeck S, Madden L, Jin X, et al.: Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-κB activation. Science 331, 468-472 (2011).
17. Malinin NL, Boldin MP, Kovalenko AV, Wallach D: MAP3K-related kinase involved in NF-κB induction by TNF, CD95 and IL-1. Nature 385, 540-544 (1997). (Pubitemid 27074673)
18. Yin L, Lin W, Wesche H, et al.: Defective lymphotoxin-b receptor-induced NF-κB transcriptional activity in NIK-deficient mice. Science 291, 2162-2165 (2001). (Pubitemid 32224449)
19. Varfolomeev E, Blankenship JW, Wayson SM, et al.: IAP antagonists induce autoubiquitination of cIAPs, NF-κB activation, and TNF-α-dependent apoptosis. Cell 131, 669-681 (2007). (Pubitemid 350087204)
20. Vince JE, Wong WW-L, Khan N, et al.: IAP antagonists target cIAP1 to induce TNF-α-dependent apoptosis. Cell 131, 682-693 (2007). (Pubitemid 350103599)
21. Gilmore TD: Introduction to NF-κB: players, pathways, perspectives. Oncogene 25, 6680-6684 (2006). (Pubitemid 44657845)
22. Annunziata CM, Davis RE, Demchenko Y, et al.: Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12, 115-130 (2007). (Pubitemid 47199123)
23. Sasaki Y, Calado DP, Derudder E, et al.: NIK overexpression amplifies, whereas ablation of its TRAF3-binding domain replaces BAFF:BAFF-R-mediated survival signals in B cells. PNAS 105(31), 10883-10888 (2008).
24. Baens M, Fevery S, Sagaert X, et al.: Selective expansion of marginal zone B cells in E?-API2-MALT1 mice is linked to enhanced IkB kinase g polyubiquitination. Cancer Res. 66(10), 5270-5277 (2006). (Pubitemid 43844951)
25. Mortier J, Masereel B, Remouchamps C, et al.: NF-κB inducing kinase inhibitors: identification of new scaffolds using virtual screening. Bioorg. Med. Chem. Lett. 20(15) 4515-4520 (2010).